Company logo

AZN - AstraZeneca PLC

LSE -> Healthcare -> Drug Manufacturers—General
Cambridge, United Kingdom

AZN price evolution
AZN
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Current assets
Cash $15567 $7636 $7832 $8072
Short term investments $62 $129 $160 $374
Net receivables $6842 $6628 $7386 $6000
Inventory $4762 $4278 $4024 $3683
Total current assets $27274 $18735 $19544 $18166
Long term investments $1120 $1060 $1147 $1215
Property, plant & equipment $9031 $8849 $8917 $8360
Goodwill & intangible assets
Total noncurrent assets $46367 $46191 $47185 $45946
Total investments
Total assets $73641 $64926 $66729 $64112
Current liabilities
Accounts payable $17729 $17370 $15785 $13406
Deferred revenue
Short long term debt $2894 $2258 $2386 $3585
Total current liabilities $22222 $21513 $20307 $18942
Long term debt $24601 $17874 $17994 $18754
Total noncurrent liabilities $35726 $28967 $30784 $31552
Total debt
Total liabilities $57965 $50496 $51107 $51917
Shareholders' equity
Retained earnings $7368 $6126 $7323 $3915
Other shareholder equity $2050 $2053 $2040 $3462
Total shareholder equity $15676 $14430 $15622 $12195
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Current assets
Cash $7832 $5369 $4831 $3324
Short term investments $160 $849 $849 $1230
Net receivables $5651 $5181 $4345 $4275
Inventory $4024 $3193 $2890 $3035
Total current assets $19544 $15563 $15591 $13150
Long term investments $1147 $1459 $922 $1036
Property, plant & equipment $8917 $8335 $7421 $7615
Goodwill & intangible assets
Total noncurrent assets $47185 $45814 $45060 $50204
Total investments
Total assets $66729 $61377 $60651 $63354
Current liabilities
Accounts payable $2350 $1774 $1720 $3611
Deferred revenue
Short long term debt $2386 $2010 $1754 $2247
Total current liabilities $20307 $18117 $16292 $16383
Long term debt $17994 $16217 $17359 $15560
Total noncurrent liabilities $30784 $28664 $30315 $30329
Total debt
Total liabilities $51107 $48250 $48183 $48394
Shareholders' equity
Retained earnings $7323 $4858 $7724 $10250
Other shareholder equity $2040 $3515 $3617 $3711
Total shareholder equity $15622 $13127 $12468 $14960
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Revenue
Total revenue $8220 $7320 $7410 $6578
Cost of revenue $2193 $1920 $1515 $1390
Gross Profit $6027 $5400 $5895 $5188
Operating activities
Research & development $1801 $1638 $1984 $1453
Selling, general & administrative $2574 $2498 $2627 $2270
Total operating expenses $7093 $5425 $5923 $5407
Operating income $1127 $1895 $1487 $1171
Income from continuing operations
EBIT
Income tax expense $214 $46 $162 $202
Interest expense
Net income
Net income $550 $1561 $1012 $648
Income (for common shares) $550 $1561 $1012 $648
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Revenue
Total revenue $26617 $24384 $22090 $22465
Cost of revenue $5270 $4824 $4213 $4137
Gross Profit $21347 $19560 $17877 $18328
Operating activities
Research & development $6094 $5320 $5266 $5412
Selling, general & administrative $9338 $8964 $8479 $7573
Total operating expenses $21455 $21460 $18703 $18788
Operating income $5162 $2924 $3387 $3677
Income from continuing operations
EBIT
Income tax expense $772 $321 -$57 -$25
Interest expense -$161
Net income
Net income $3196 $1335 $2155 $3001
Income (for common shares) $3196 $1335 $2155 $3001
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Net income $764 $1608 $1167 $853
Operating activities
Depreciation $753 $797 $797 $801
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $892 $1934 $1798 $1822
Investing activities
Capital expenditures -$353 -$469 -$548 -$705
Investments
Total cash flows from investing -$236 $555 $138 -$580
Financing activities
Dividends paid -$2469 -$1174
Sale and purchase of stock $4 $5 $19 $2
Net borrowings $7284 -$244 -$2229 $2423
Total cash flows from financing $7289 -$2731 -$2210 $1243
Effect of exchange rate $15 -$67 $26 $4
Change in cash and equivalents $7960 -$309 -$248 $2489
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018 31 Dec 2017
Net income $3916 $1548 $1993 $2227
Operating activities
Depreciation $3149 $3762 $3753 $3036
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $4799 $2969 $2618 $3578
Investing activities
Capital expenditures -$2606 -$2460 -$1371 -$1620
Investments
Total cash flows from investing -$285 -$657 $963 -$2328
Financing activities
Dividends paid -$3572 -$3592 -$3484 -$3519
Sale and purchase of stock $30 $3525 $34 $43
Net borrowings $1440 -$1702 $1473 $560
Total cash flows from financing -$2203 -$1765 -$2044 -$2936
Effect of exchange rate $12 $5 -$38 -$66
Change in cash and equivalents $2323 $552 $1499 -$1752
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue $29.53B
EBITDA N/A
EBIT N/A
Net Income $3.77B
Revenue Q/Q 31.00%
Revenue Y/Y 14.90%
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA 5.60%
ROE 26.04%
Debt/Equity 3.27
Net debt/EBITDA N/A
Current ratio 1.23
Quick ratio 1.01